<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515551</url>
  </required_header>
  <id_info>
    <org_study_id>IMCnyeso-101</org_study_id>
    <nct_id>NCT03515551</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers</brief_title>
  <official_title>A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunocore Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunocore Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMCnyeso is a new biological therapy designed for the treatment of cancers which express
      NY-ESO-1 and/or LAGE-1A. This is a first-in-human trial designed to evaluate the safety and
      efficacy of IMCnyeso in adult patients who have the appropriate HLA-A2 tissue marker and
      whose cancer is positive for NY-ESO-1 and/or LAGE-A1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open label, dose finding Phase 1/2 study of single agent IMCnyeso
      administered in patients with NY-ESO-1 and/or LAGE-A1 positive tumors. The primary objective
      of the dose escalation phase (Arm 1) is to determine the maximum tolerated dose (MTD) and/or
      recommended Phase II dose (RP2D) of IMCnyeso in patients with advanced solid tumors.
      Preliminary efficacy will be evaluated in Arm 2.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Incidence of dose-limiting toxicities (DLT)</measure>
    <time_frame>from first dose to end of DLT period (up until Day 28 after first dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: incidence and severity of adverse events (AE)</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: changes in laboratory parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Abnormalities will be classified according to NCI CTCAE version 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: changes in body temperature</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Body temperature will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: changes in pulse</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Pulse will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: changes in respiratory rate</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Respiratory rate will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: changes in blood pressure</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Blood pressure will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: changes in electrocardiogram parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>QTcF interval absolute values and changes from Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: dose interruptions, reductions, and discontinuations</measure>
    <time_frame>from first dose through last dose (anticipated up to 1 year)</time_frame>
    <description>Tolerability of study treatment will be assessed by summarizing the number of treatment dose interruptions and dose reductions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Best overall response (BOR)</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: incidence and severity of adverse events (AE)</measure>
    <time_frame>first dose to 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: changes in laboratory parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Abnormalities will be classified according to NCI CTCAE version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: changes in body temperature</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Body temperature will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: changes in pulse</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Pulse will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: changes in respiratory rate</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Respiratory rate will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: changes in blood pressure</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>Blood pressure will be measured throughout the study. Both absolute values and changes from Baseline will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: changes in electrocardiogram parameters</measure>
    <time_frame>from first dose to 30 days after the last dose</time_frame>
    <description>QTcF interval absolute values and changes from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: dose interruptions, reductions, and discontinuations</measure>
    <time_frame>first dose through last dose (anticipated up to 1 year)</time_frame>
    <description>Tolerability of study treatment will be assessed by summarizing the number of treatment dose interruptions and dose reductions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Best overall response (BOR)</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from first dose to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>2 weeks (AUC will be assessed weekly for 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The maximum observed plasma drug concentration after single dose administration (Cmax)</measure>
    <time_frame>2 weeks (AUC will be assessed weekly for 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>2 weeks (AUC will be assessed weekly for 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics The elimination half-life (t1/2)</measure>
    <time_frame>2 weeks (AUC will be assessed weekly for 2 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity the incidence of anti-IMCnyeso antibody formation Immunogenicity the incidence of anti-IMCnyeso antibody formation</measure>
    <time_frame>2 weeks (AUC will be assessed weekly for 2 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Select Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>IMCnyeso dose Escalation Phase with approximately 4-10 cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase (Arm 1) n=approximately 27 patients to establish the MTD/RP2D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMCnyeso expansion with 3 cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=9-24/cohort treated at the RP2D to make a preliminary assessment of the anti-tumor activity of IMCnyeso</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMCnyeso</intervention_name>
    <description>Weekly IV infusions of IMCnyeso</description>
    <arm_group_label>IMCnyeso dose Escalation Phase with approximately 4-10 cohorts</arm_group_label>
    <arm_group_label>IMCnyeso expansion with 3 cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HLA-A*0201 positive

          2. NY-ESO-1 and/or LAGE-1A positive tumor

          3. ECOG PS 0 or 1

          4. Selected advanced solid tumors

          5. Relapsed from, refractory to, or intolerant of standard therapy

          6. Measurable disease per RECIST v1.1

          7. If applicable, must agree to use highly effective contraception

        Exclusion Criteria:

          1. Symptomatic or untreated central nervous system metastasis

          2. Inadequate washout from prior anticancer therapy

          3. Significant ongoing toxicity from prior anticancer treatment

          4. Impaired baseline organ function as evaluated by out-of-range laboratory values

          5. Clinically significant cardiac disease

          6. Active infection requiring systemic antibiotic therapy

          7. Known history of human immunodeficiency virus (HIV)

          8. Active hepatitis B virus (HBV) or hepatitis C virus (HCV)

          9. Ongoing treatment with systemic steroids or other immunosuppressive therapies

         10. Significant secondary malignancy

         11. Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaad Abdullah, MD</last_name>
    <role>Study Director</role>
    <affiliation>Immunocore Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shannon Marshall</last_name>
    <phone>484-534-5261</phone>
    <email>clinicaltrials@immunocore.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Breelyn Wilky, MD</last_name>
      <phone>303-724-6429</phone>
    </contact>
    <investigator>
      <last_name>Breelyn Wilky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mihaela Druta, MD</last_name>
      <phone>813-745-3242</phone>
    </contact>
    <investigator>
      <last_name>Mihaela Druta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Milhem</last_name>
      <phone>319-356-2324</phone>
    </contact>
    <investigator>
      <last_name>Mohammed Milhem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirish Gadgeel, MD</last_name>
      <phone>313-576-8753</phone>
    </contact>
    <investigator>
      <last_name>Shirish Gadgeel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Van Tine, MD</last_name>
      <phone>314-747-3096</phone>
    </contact>
    <investigator>
      <last_name>Brian Van Tine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra D'Angelo, MD</last_name>
      <phone>646-888-4159</phone>
    </contact>
    <contact_backup>
      <last_name>Sandra D'Angelo, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takami Sato, MD</last_name>
      <phone>215-955-8874</phone>
    </contact>
    <investigator>
      <last_name>Takami Sato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC - Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Burgess, MD</last_name>
      <phone>412-647-2811</phone>
    </contact>
    <investigator>
      <last_name>Melissa Burgess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology NASH - SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Johnson</last_name>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Rodon Ahnert, MD</last_name>
      <phone>713-792-5603</phone>
    </contact>
    <investigator>
      <last_name>Jordi Rodon Ahnert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute at The University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sumati Gupta</last_name>
      <phone>801-585-0303</phone>
    </contact>
    <investigator>
      <last_name>Sumati Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Butler</last_name>
      <phone>4169464501</phone>
      <phone_ext>2003</phone_ext>
    </contact>
    <investigator>
      <last_name>Marcus Butler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendrik Tobias Arkenau, MD</last_name>
      <phone>(440) 203-2195 x239</phone>
    </contact>
    <investigator>
      <last_name>Hendrik Tobias Arkenau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Thistlethwaite, MD</last_name>
    </contact>
    <contact_backup>
      <phone>+44 (0) 161 9182323</phone>
    </contact_backup>
    <investigator>
      <last_name>Fiona Thistlethwaite, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juanita Lopez, MD</last_name>
    </contact>
    <contact_backup>
      <phone>(0)2086613539</phone>
    </contact_backup>
    <investigator>
      <last_name>Juanita Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2018</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IMCnyeso</keyword>
  <keyword>Immunotherapy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

